B of A Securities Downgrades Achilles Therapeutics to Underperform, Lowers Price Target to $0.5
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad has downgraded Achilles Therapeutics (ACHL) from Buy to Underperform, significantly reducing the price target from $7 to $0.5.

December 14, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Achilles Therapeutics' stock rating has been downgraded by B of A Securities from Buy to Underperform, and the price target has been lowered from $7 to $0.5.
The downgrade from Buy to Underperform by a major analyst indicates a negative outlook on the company's stock performance. The substantial decrease in the price target from $7 to $0.5 suggests a significant loss of confidence in the company's value, which is likely to have a negative impact on investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100